These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35441522)

  • 1. Real-world treatment patterns and overall survival in
    Atkins MB; Julian C; Secrest MH; Lee J; Abajo-Guijarro AM; McKenna E
    Future Oncol; 2022 Jun; 18(18):2233-2245. PubMed ID: 35441522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
    Betof Warner A; Tarhini A; Kang B; Nakasato A; Ling YL; Shah R; Tang J; Patel J
    Melanoma Res; 2023 Feb; 33(1):38-49. PubMed ID: 36545921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma.
    Kartolo A; Deluce J; Hopman WM; Liu L; Baetz T; Ernst S; Lenehan JG
    Curr Oncol; 2022 Mar; 29(3):1501-1513. PubMed ID: 35323326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
    Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
    Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
    Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment management for
    Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
    Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
    Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
    Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
    [No Abstract]   [Full Text] [Related]  

  • 10. The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study.
    Haist M; Stege H; Ebner R; Fleischer MI; Loquai C; Grabbe S
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line immunotherapy versus targeted therapy in patients with
    Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
    Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
    [No Abstract]   [Full Text] [Related]  

  • 13. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.
    Ferrucci PF; Lens M; Cocorocchio E
    Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
    Kiniwa Y; Okuyama R
    Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Gogas H
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):53-62. PubMed ID: 31903803
    [No Abstract]   [Full Text] [Related]  

  • 17. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France.
    Sassolas B; Leccia MT; Godard C; Benmahamed L; Flinois A; Levy-Bachelot L; Bédane C
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):587-594. PubMed ID: 28960564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.
    Mangana J; Zihler D; Bossart S; Brönnimann D; Zachariah R; Gérard CL
    Melanoma Res; 2022 Oct; 32(5):366-372. PubMed ID: 35855650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.
    Trojaniello C; Sparano F; Cioli E; Ascierto PA
    Curr Oncol Rep; 2023 Jun; 25(6):623-634. PubMed ID: 36995534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.